Anthera Pharmaceutical ... -80%

This is biotech "at its best".
An expert review board gave this drug an approval of passing, with a shelf offering of about $100 millions.
And now ... Sollpura has just failed to achieve the desired results in a Phase 3 clinical study ...

Luckily, I closed one trade with a win for this stock.

Conclusion: Stay away from small biotech firms!
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
HE עברית
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out